Payment overview · 2025
General Payments
$782.17
52 reported records · 13 companies
Healthcare provider profile · identity verified
Cara Hindel
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ZANESVILLE, OH · NPI 1306227921
Verified facts
What the public records show
CMS Open Payments records show Cara Hindel received $782.17 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $339.47 | 43.4% | 27 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.35 | 12.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.20 | 7.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $53.44 | 6.8% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $48.81 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.41 | 4.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.58 | 3.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.44 | 3.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $25.15 | 3.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.61 | 2.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.70 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.40 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.61 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $782.17 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $190.08 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $146.67 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $92.88 | 11 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $56.51 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $53.44 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.29 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $48.81 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $48.81 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.06 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.06 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.41 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.58 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.44 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.58 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 116 |
| Omeprazole | Omeprazole | 397 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 329 | 94 |
| Lisinopril | Lisinopril | 318 | 72 |
| Losartan Potassium | Losartan Potassium | 269 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 258 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 54 |
| Metformin Hcl | Metformin Hcl | 204 | 43 |
| Trazodone Hcl | Trazodone Hcl | 202 | 38 |
| Fenofibrate | Fenofibrate Nanocrystallized | 195 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 35 |
| Sertraline Hcl | Sertraline Hcl | 181 | 37 |
| Furosemide | Furosemide | 173 | 41 |
| Potassium Chloride | Potassium Chloride | 142 | 27 |
| Alendronate Sodium | Alendronate Sodium | 141 | 32 |
| Carvedilol | Carvedilol | 139 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 47 |
| Gabapentin | Gabapentin | 139 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 137 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 23 |
| Metformin Hcl Er | Metformin Hcl | 125 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 38 |
| Buspirone Hcl | Buspirone Hcl | 113 | 23 |
| Meloxicam | Meloxicam | 108 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 26 |
| Fenofibrate | Fenofibrate,micronized | 103 | 15 |
| Montelukast Sodium | Montelukast Sodium | 100 | 20 |
| Ozempic | Semaglutide | 99 | 21 |
| Famotidine | Famotidine | 89 | 14 |
| Jardiance | Empagliflozin | 86 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 12 |
| Glipizide Er | Glipizide | 80 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 20 |
| Ondansetron Odt | Ondansetron | 75 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | suppressed |
| Atenolol | Atenolol | 67 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 13 |
| Topiramate | Topiramate | 61 | 12 |
| Fenofibrate | Fenofibrate | 59 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | suppressed |
| Pregabalin | Pregabalin | 55 | 12 |
| Simvastatin | Simvastatin | 55 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 22 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 16 |
| Ezetimibe | Ezetimibe | 51 | 14 |
| Mirtazapine | Mirtazapine | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 11 |
| Glipizide | Glipizide | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 16 |
| Tramadol Hcl | Tramadol Hcl | 44 | 18 |
| Alprazolam | Alprazolam | 43 | 11 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Prednisone | Prednisone | 43 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 24 |
| Eliquis | Apixaban | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Glyburide | Glyburide | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Lovastatin | Lovastatin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $782.17 · 52 records | ABBVIE INC. | AIRSUPRA, ARISTADA, CAPLYTA, CREON, ELIQUIS, FARXIGA, Kerendia, Korlym, LINZESS, LYBALVI, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Veozah, Wegovy, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error